Support
Contact us
English
Back to lobby 
Gil Ben-Horin Published: Sep 16, 2017
A retrospective study performed at Centre Hospitalier Universitaire Vaudois (CHUV) in Switzerland aimed to evaluate the effect of Levosimendan on cardiac output parameters in cardiac children with low cardiac output syndrome (LCOS). This study is one of the largest studies relating to the efficacy of Levosimendan in children with LCOS, which remains a major complication after congenital heart surgery. Demographic and clinical data were collected from MetaVision. The authors found that in accordance with other paediatric studies done in similar settings, Levosimendan helps stabilise and can even improve the haemodynamic condition of patients when the usual inotropic treatments have failed. It may prevent the need for mechanical cardiac support, although this should be confirmed by additional studies. They conclude that, “Levosimendan is a cardioprotective drug that will undoubtedly become part of the standard of care of the prevention and management of LCOS.”
Book a demo 
Login to Support Portal 
